Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

A8236

Sigma-Aldrich

AN-9

≥95% (HPLC)

Sinónimos:

Pivaloyloxymethyl butyrate, Pivanex

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H18O4
Número de CAS:
122110-53-6
Peso molecular:
202.25
Número MDL:
MFCD00209896
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
329770954
NACRES:
NA.77

Análisis

≥95% (HPLC)

formulario

oil

color

colorless to slightly yellow

solubilidad

DMSO: ≥10 mg/mL

temp. de almacenamiento

−20°C

cadena SMILES

CCCC(=O)OCOC(=O)C(C)(C)C

InChI

1S/C10H18O4/c1-5-6-8(11)13-7-14-9(12)10(2,3)4/h5-7H2,1-4H3

Clave InChI

GYKLFBYWXZYSOW-UHFFFAOYSA-N

Aplicación

AN-9 is a HDAC inhibitor with antimetastatic and antiangiogenic properties. These anticancer activities are thought to occur by reducing vascularization and the expression of bFGF and HIF-1α.

Acciones bioquímicas o fisiológicas

HDAC Inhibitor tested as an anti-cancer drug; butyric acid pro-drug

Código de clase de almacenamiento

12 - Non Combustible Liquids

Clase de riesgo para el agua (WGK)

nwg

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Y Zimra et al.
Journal of cancer research and clinical oncology, 123(3), 152-160 (1997-01-01)
A novel butyric acid derivative, pivaloyloxymethyl butyrate, AN-9, was previously shown to be a potent differentiating agent. AN-9 exerts a significant anticancer activity in vitro and in vivo. In all the activities examined, AN-9 was more potent than butyric acid.
E Rabizadeh et al.
Leukemia research, 31(8), 1115-1123 (2007-02-03)
Chronic myelogenous leukemia (CML) is associated with the high TK activity chimeric protein BCR-ABL, known to contribute to cell tumorogenicity, resistance to apoptosis and differentiation. STI571, the TK inhibitor, is the current treatment for CML. One possible approach to overcome
T Kasukabe et al.
British journal of cancer, 75(6), 850-854 (1997-01-01)
A derivative of butyric acid, pivalyloxymethyl butyrate (AN-9), inhibited the proliferation and induced apoptosis of mouse monocytic leukaemia Mm-A cells, although sodium butyrate, but not AN-9, induced differentiation of the cells. AN-9 and DNA-specific antineoplastic agents synergistically inhibited the growth
L L Siu et al.
Investigational new drugs, 16(2), 113-119 (1998-12-16)
The anti-proliferative effects of pivaloyloxymethyl butyrate (AN-9), a butyric acid (BA) derivative with potent tumor-differentiating properties both in vitro and in vivo, was evaluated against colorectal, breast, lung, ovarian, renal cell, bladder, and other types of tumor colony-forming units in
Ayse Batova et al.
Blood, 100(9), 3319-3324 (2002-10-18)
The novel prodrug of butyric acid, pivaloyloxymethyl butyrate (AN-9), a histone deacetylase inhibitor, shows great promise as an effective and relatively nontoxic anticancer agent for solid malignancies. However, little is known about its effects on hematopoietic malignancies. In this study
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico